InvestorsHub Logo
Followers 1
Posts 114
Boards Moderated 0
Alias Born 12/26/2017

Re: None

Tuesday, 11/12/2019 7:36:24 PM

Tuesday, November 12, 2019 7:36:24 PM

Post# of 34625
The best thing MRKR has going for it is stand alone CRs in some hematologic malignancies and clear evidence of antigen/epitope spreading in hematologic and solid tumors. Now they need to start combining the treatment with other immunotherapy treatments that work such as anti-PD1 and anti-CTLA4 to go for synergism. Multi-TAA has no side effects so the combos should be as safe as the checkpoint blockers. What's the hold up? Why doesn't Baylor do this?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News